Guidelines for Dental Management of Antiresorptive Therapy

Abstract

Antiresorptive therapy, commonly prescribed for osteoporosis and metastatic bone disease, is associated with a risk of medication-related osteonecrosis of the jaw (MRONJ). Dental practitioners play a pivotal role in the prevention, early diagnosis, and management of complications related to antiresorptive agents. This comprehensive review synthesizes current guideline-based recommendations, epidemiology, pathophysiological mechanisms, risk stratification, clinical features, diagnostic criteria, and management strategies, emphasizing practical implications for dental professionals and multidisciplinary teams.

Introduction

Antiresorptive agents, including bisphosphonates and denosumab, are integral to the management of osteoporosis, Paget’s disease, and bone metastases from malignancies. Their efficacy in reducing skeletal-related events is well established. However, dental management of patients receiving these therapies is complex due to the risk of MRONJ, a potentially debilitating complication. This article provides an evidence-based synthesis of guidelines and recent advances for dental practitioners who manage patients on antiresorptive therapy, ensuring optimal oral health outcomes and minimizing risk.

Epidemiology / Disease Burden

MRONJ is a rare but serious adverse event, with prevalence estimates varying by indication, medication type, dosage, and administration route. In oncology patients receiving intravenous bisphosphonates, incidence ranges from 1% to 15%, whereas in patients treated for osteoporosis with oral bisphosphonates, prevalence is substantially lower (approximately 0.01% to 0.1%). With increasing use of denosumab and emerging antiresorptives, the absolute number of at-risk patients is rising globally, underscoring the importance of dental vigilance.

Pathophysiology

Antiresorptive agents inhibit osteoclast-mediated bone resorption, reducing bone turnover and remodeling. Bisphosphonates bind to bone mineral and induce osteoclast apoptosis, while denosumab, a monoclonal antibody to RANKL, blocks osteoclast activation. Suppressed bone turnover impairs the jaw’s ability to repair microtrauma, especially following dental extractions or infection. Local factors such as poor oral hygiene or trauma can precipitate necrosis in susceptible individuals. The unique oral microbial milieu and high bone turnover in jaws further predispose to MRONJ compared to other skeletal sites.

Risk Factors

Risk stratification is central to guideline-based management. Major risk factors include type, dose, and duration of antiresorptive therapy, intravenous versus oral administration, and concurrent corticosteroid or antiangiogenic therapy. Dental risk factors encompass invasive procedures (especially extractions), pre-existing periodontal or periapical disease, ill-fitting dentures, and poor oral hygiene. Systemic factors such as advanced age, diabetes, and smoking further increase risk. Individualized risk assessment guides decision-making on dental procedures and preventive measures.

Clinical Features

MRONJ is characterized by exposed bone in the maxillofacial region persisting for more than eight weeks in patients with current or prior antiresorptive therapy and no history of head and neck radiation. Symptoms can range from asymptomatic bone exposure to pain, swelling, purulent discharge, fistula formation, and pathologic fracture. Non-exposed variants present with unexplained jaw pain or swelling, often preceding overt bone exposure. Early detection is crucial for improved prognosis.

Diagnosis

Diagnosis is primarily clinical but supported by imaging and exclusion of malignancy or radiation history. Panoramic radiographs, cone-beam CT, or MRI may reveal bone sclerosis, sequestrum, or periosteal reaction. Staging is based on clinical findings: Stage 0 (no bone exposure but nonspecific symptoms), Stage 1 (exposed asymptomatic bone), Stage 2 (exposed bone with infection and symptoms), and Stage 3 (extensive involvement, pathologic fracture, or extraoral fistula). Biopsy is reserved for atypical presentations to rule out metastasis or other pathologies.

Treatment & Management

Prevention is paramount. Dental assessment and necessary interventions should precede initiation of antiresorptive therapy whenever possible. During therapy, non-invasive dental care and meticulous oral hygiene are advised. Invasive procedures should be minimized or performed with caution, ideally after consultation with prescribing physicians. For established MRONJ, conservative management includes antimicrobial mouth rinses, systemic antibiotics, and pain control. Surgical intervention is reserved for refractory or advanced cases, emphasizing conservative debridement over extensive resection. Regular follow-up and patient education are essential.

Recent Advances / Emerging Therapies

Recent advances focus on risk mitigation, including drug holiday protocols, use of biomarkers (e.g., CTX), and regenerative approaches such as platelet-rich fibrin or laser therapy. Multidisciplinary pathways integrating dental, medical, and oncology teams have shown improved outcomes. Emerging therapies target modulation of osteoclast activity with reduced MRONJ risk profiles. Ongoing research into local delivery of antiresorptives and alternative dosing regimens may further reduce oral complications without compromising skeletal benefits.

Guideline Recommendations

Guidelines from organizations such as the American Association of Oral and Maxillofacial Surgeons (AAOMS), American Dental Association (ADA), and International Task Forces emphasize proactive dental screening, patient education, and risk-based management. Key recommendations include: conducting thorough dental evaluations before antiresorptive initiation, minimizing invasive procedures during therapy, adopting conservative approaches for MRONJ management, and maintaining close interprofessional communication. Drug holidays may be considered for low-risk osteoporosis patients requiring elective extractions, though evidence is evolving. Documentation and patient consent regarding MRONJ risk are advised.

Conclusion

Dental management of patients on antiresorptive therapy demands a nuanced, guideline-driven approach integrating risk assessment, preventive strategies, and multidisciplinary collaboration. Early intervention, patient education, and adherence to evidence-based protocols are critical to reducing MRONJ incidence and optimizing oral health outcomes. Ongoing research and refinement of clinical pathways will continue to enhance the safety and efficacy of dental care for this growing patient population.